IG asked to probe Graham harassment

Share this article:
Finance Committee chairman Sen. Chuck Grassley (R-IA) has asked the HHS inspector general to find out how an FDA employee worked "in concert with a pharmaceutical drug maker to discredit the FDA scientist who publicized information about the safety risks of the drug Vioxx."

The request was based on the handwritten notes of a Merck executive about his meeting with a high-level FDA official that indicated the FDA official had suggested the firm release its critique of Dr. David Graham. “This evidence makes it look like FDA hung Dr. Graham out to dry,” the senator said. “If so, the message sent to the rank-and-file is, ‘We're not with you, we're with the industry.'”

The Merck executive was named as Dr. Ned Braunstein, Merck Research Labs senior director; and the FDA official as Dr. Brian Harvey, director of the Division of Gastrointestinal and Coagulation Drug Products.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...